258 related articles for article (PubMed ID: 19054822)
1. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment.
Simon TA; Smitten AL; Franklin J; Askling J; Lacaille D; Wolfe F; Hochberg MC; Qi K; Suissa S
Ann Rheum Dis; 2009 Dec; 68(12):1819-26. PubMed ID: 19054822
[TBL] [Abstract][Full Text] [Related]
2. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.
Simon TA; Askling J; Lacaille D; Franklin J; Wolfe F; Covucci A; Suissa S; Hochberg MC;
Arthritis Res Ther; 2010; 12(2):R67. PubMed ID: 20398273
[TBL] [Abstract][Full Text] [Related]
3. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program.
Weinblatt ME; Moreland LW; Westhovens R; Cohen RB; Kelly SM; Khan N; Pappu R; Delaet I; Luo A; Gujrathi S; Hochberg MC
J Rheumatol; 2013 Jun; 40(6):787-97. PubMed ID: 23588946
[TBL] [Abstract][Full Text] [Related]
4. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
[TBL] [Abstract][Full Text] [Related]
5. Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries.
Dominique A; Hetland ML; Finckh A; Gottenberg JE; Iannone F; Caporali R; Kou TD; Nordstrom D; Hernandez MV; Sánchez-Piedra C; Sánchez-Alonso F; Pavelka K; Bond TC; Simon TA
Arthritis Res Ther; 2023 Jun; 25(1):101. PubMed ID: 37308978
[TBL] [Abstract][Full Text] [Related]
6. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis.
Simon TA; Thompson A; Gandhi KK; Hochberg MC; Suissa S
Arthritis Res Ther; 2015 Aug; 17(1):212. PubMed ID: 26271620
[TBL] [Abstract][Full Text] [Related]
7. How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries.
Askling J; Berglind N; Franzen S; Frisell T; Garwood C; Greenberg JD; Ho M; Holmqvist M; Horne L; Inoue E; Michaud K; Nyberg F; Pappas DA; Reed G; Tanaka E; Tran TN; Verstappen SM; Yamanaka H; Wesby-van Swaay E; Symmons D
Ann Rheum Dis; 2016 Oct; 75(10):1789-96. PubMed ID: 26621482
[TBL] [Abstract][Full Text] [Related]
8. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
9. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.
Bathon J; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Moniz Reed D; Helfrick R; Westhovens R
Ann Rheum Dis; 2011 Nov; 70(11):1949-56. PubMed ID: 21821865
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors.
Westhovens R; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Helfrick R; Bathon J
Ann Rheum Dis; 2009 Dec; 68(12):1870-7. PubMed ID: 19124524
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
12. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
[TBL] [Abstract][Full Text] [Related]
14. [Selective co-stimulation blockade. CTLA4-Ig (Abatacept)].
Alten R; Märker-Hermann E
Z Rheumatol; 2010 Sep; 69(7):601-7. PubMed ID: 20703487
[TBL] [Abstract][Full Text] [Related]
15. Safety profile of abatacept in rheumatoid arthritis: a review.
Khraishi M; Russell A; Olszynski WP
Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
[TBL] [Abstract][Full Text] [Related]
16. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.
Harigai M; Nanki T; Koike R; Tanaka M; Watanabe-Imai K; Komano Y; Sakai R; Yamazaki H; Koike T; Miyasaka N
Mod Rheumatol; 2016 Sep; 26(5):642-50. PubMed ID: 26873430
[TBL] [Abstract][Full Text] [Related]
17. Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study.
Montastruc F; Renoux C; Dell'Aniello S; Simon TA; Azoulay L; Hudson M; Suissa S
Rheumatology (Oxford); 2019 Apr; 58(4):683-691. PubMed ID: 30535094
[TBL] [Abstract][Full Text] [Related]
18. Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs.
Takeuchi T; Matsubara T; Urata Y; Suematsu E; Ohta S; Honjo S; Abe T; Yamamoto A; Miyasaka N;
Mod Rheumatol; 2014 Sep; 24(5):744-53. PubMed ID: 24754273
[TBL] [Abstract][Full Text] [Related]
19. Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study.
de Germay S; Bagheri H; Despas F; Rousseau V; Montastruc F
Rheumatology (Oxford); 2020 Sep; 59(9):2360-2367. PubMed ID: 31880308
[TBL] [Abstract][Full Text] [Related]
20. Use of abatacept in rheumatoid arthritis.
von Kempis J; Dudler J; Hasler P; Kyburz D; Tyndall A; Zufferey P; Villiger PM
Swiss Med Wkly; 2012; 142():w13581. PubMed ID: 22581564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
